Table 5.
Mortality as outcome among admitted cancer patients with SARS-CoV-2 infection.
| n (%) | Mortality rate | p valueT |
|---|---|---|
| Primary tumour site | ||
| Lung,% (n/N) | 40% (6/15) | 0.17 |
| Other site,% (n/N) | 21% (10/48) | |
| Metastatic status | ||
| Non-metastatic, % (n/N) | 9% (1/11) | 0.17 |
| Metastatic, % (n/N) | 29% (15/52) | |
| Pulmonary extension | ||
| Yes, % (n/N) | 16% (6/38) | 0.006 |
| No, % (n/N) | 40% (10/25) | |
| Severe neutropenia | ||
| No | 0/60 | 0.01 |
| Yes | 3/3 (100%) | |
| Radiological pattern | ||
| Unilobar/bilobar, %(n/N) | 0%, (0/30) | <0∙001 |
| Bilateral, % (n/N) | 48%, (16/33) | |
| Sex | ||
| Male | 26% (9/34) | 0.83 |
| Female | 24% (7/29) | |
| Comorbidities (N = 63) | ||
| Previous anaemia, % (n/N) | 5% (3/63) | 0.71 |
| HTA | 16% (10/63) | 0.40 |
| Diabetes | 5% (3/63) | 0.70 |
| Chronic kidney disease | 3% (2/63) | 0.43 |
| Cardiomyopathy | 1.6% (1/63) | 0.13 |
| Chronic obstructive pulmonary disease | 3% (2/63) | 0.69 |
| Previous VTE | 9% (6/63) | 0.05 |
| Previous ACEi/ARBs | 1.6% (1/63) | 0.37 |
| Anticoagulant therapy | 5% (3/63) | 0.22 |
| Previous corticosteroids | 5% (3/63) | 0.15 |
Numbers are expressed as % and n/N, being n the number of deaths and N the total number of patients in that category except for comorbidities, where N is referred to the total number of patients in the study.
T p values for Fisher's exact test.